stocks logo

ENLV Valuation

Enlivex Therapeutics Ltd
$
0.897
-0.023(-2.500%)
  • Overview
  • Forecast
  • Valuation

ENLV Relative Valuation

ENLV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENLV is overvalued; if below, it's undervalued.
Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.90
P/B
Median3y
1.16
Median5y
1.80
-60.26
FCF Yield
Median3y
-54.74
Median5y
-36.64

Competitors Valuation Multiple

The average P/S ratio for ENLV's competitors is 0.79, providing a benchmark for relative valuation. Enlivex Therapeutics Ltd Corp (ENLV) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
stocks logo
ENLV.O
Enlivex Therapeutics Ltd
Loss
Average P/S: 0.79
19.74M
stocks logo
IPA.O
Immunoprecise Antibodies Ltd
0.91
-0.41%
19.74M
stocks logo
CMMB.O
Chemomab Therapeutics Ltd
Loss
20.11M
stocks logo
CALC.O
CalciMedica Inc
Loss
20.69M
stocks logo
PMN.O
ProMIS Neurosciences Inc
2.52
18.29M
stocks logo
MURA.O
Mural Oncology PLC
1.29
17.75M

People Also Watch

stocks logo
MCBS
Metrocity Bankshares Inc
25.820
USD
+1.69%
stocks logo
VTS
Vitesse Energy Inc
20.420
USD
+3.44%
stocks logo
ADTN
ADTRAN Holdings Inc
7.620
USD
+1.06%
stocks logo
SCVL
Shoe Carnival Inc
18.780
USD
-3.10%
stocks logo
LVWR
LiveWire Group Inc
2.360
USD
+3.96%
stocks logo
ADV
Advantage Solutions Inc
1.200
USD
-6.25%
stocks logo
OSBC
Old Second Bancorp Inc
14.450
USD
-0.55%
stocks logo
ICLK
iClick Interactive Asia Group Ltd
9.240
USD
+10.00%
stocks logo
GCT
GigaCloud Technology Inc
11.700
USD
+1.04%
stocks logo
CEVA
CEVA Inc
23.110
USD
+1.14%

FAQ

arrow icon

Is Enlivex Therapeutics Ltd (ENLV) currently overvalued or undervalued?

Enlivex Therapeutics Ltd (ENLV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Enlivex Therapeutics Ltd (ENLV) is between to according to relative valuation methord.
arrow icon

What is Enlivex Therapeutics Ltd (ENLV) fair value?

arrow icon

How does ENLV's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Enlivex Therapeutics Ltd (ENLV) as of Apr 14 2025?

arrow icon

What is the current FCF Yield for Enlivex Therapeutics Ltd (ENLV) as of Apr 14 2025?

arrow icon

What is the current Forward P/E ratio for Enlivex Therapeutics Ltd (ENLV) as of Apr 14 2025?

arrow icon

What is the current Forward P/S ratio for Enlivex Therapeutics Ltd (ENLV) as of Apr 14 2025?